Q linea

Q linea R&D per Employee

The R&D Spending per Employee of Q linea (QLINEA.ST) as of Nov 3, 2026 is 1.05 M SEK. In the previous year, R&D Spending per Employee was 1.25 M SEK — a change of -15.71% (lower).

R&D per Employee

1.05 MSEK

YoY

-15.71%

Last updated:

R&D Spending per Employee of Q linea is 2023 1.05 M SEK. R&D Spending per Employee of Q linea was 2022 1.25 M SEK. It decreases by -15.71% lower compared to the previous year.

The Q linea R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2017
439,795.08 SEK
Jan 1, 2018
804,327.87 SEK
Jan 1, 2019
997,426.23 SEK
Jan 1, 2020
1.28 M SEK
Jan 1, 2021
1.29 M SEK
Jan 1, 2022
1.25 M SEK
Jan 1, 2023
1.05 M SEK
The Q linea R&D per Employee history
YEARR&D per EmployeeYoY
1.05 MSEK-15.71%
1.25 MSEK-3.17%
1.29 MSEK+0.36%
1.28 MSEK+28.52%
997,426.23SEK+24.01%
804,327.87SEK+82.89%
439,795.08SEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Q linea Stock analysis

What does Q linea do? Q-linea AB develops and manufactures in-vitro diagnostic solutions for infectious diseases, focusing on antibiotic susceptibility testing. The company's core product, ASTar, is a fully-automated instrument that provides susceptibility profiles within three to six hours directly from positive blood cultures. This enables early targeted antibiotic administration for sepsis identification in hospital patients, primarily serving hospital laboratories. The firm measures bacteria's antimicrobial susceptibility using its own disposables, which are integral to the ASTar system's operation. Q-linea AB's revenue model is based on selling the ASTar instrument and its associated disposables to hospital laboratories. The company's product is specifically designed for sepsis identification in hospital settings, where rapid and accurate antibiotic susceptibility testing is critical. By providing a faster solution than traditional methods, Q-linea targets hospital labs seeking to improve patient outcomes in sepsis cases. The company operates as a holding company with a focus on developing and manufacturing IVD solutions. Its primary customers are hospital laboratories, which purchase the ASTar system and disposables to streamline their diagnostic processes. The firm's business model centers on the sale of both the instrument and the consumable disposables, creating recurring revenue streams from ongoing disposables usage. Q linea is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Q linea stock

R&D Spending per Employee of Q linea is 1.05 M SEK in 2023.

R&D Spending per Employee of Q linea changed from 1.25 M SEK to 1.05 M SEK, representing a -15.71% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Q linea since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Q linea historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Q linea

All Key Metrics — Q linea